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Rapidly evolving research examining the extended role of human beta-defensins (hBDs)
in chemoattraction, innate immune-mediated response, and promotion of angiogenesis
suggest that the collective effects of hBDs extend well beyond their antimicrobial mecha-
nism(s). Indeed, the numerous basic cellular functions associated with hBDs demonstrate
that these peptides have dual impact on health, as they may be advantageous under certain
conditions, but potentially detrimental in others.The consequences of these functions are
reflected in the overexpression of hBDs in diseases, such as psoriasis, and recently the
association of hBDs with pro-tumoral signaling.The mechanisms regulating hBD response
in health and disease are still being elucidated. Clearly the spectrum of function now attrib-
uted to hBD regulation identifies these molecules as important cellular regulators, whose
appropriate expression is critical for proper immune surveillance; i.e., expression of hBDs
in proximity to areas of cellular dysregulation may inadvertently exacerbate disease pro-
gression. Understanding the mechanism(s) that regulate contextual signaling of hBDs is an
important area of concentration in our laboratories. Using a combination of immunologic,
biochemical, and molecular biologic approaches, we have identified signaling pathways
associated with hBD promotion of immune homeostasis and have begun to dissect the
inappropriate role that beta-defensins may assume in disease.
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ANTIMICROBIAL PEPTIDES
Antimicrobial peptides (AMPs) are expressed by various human
cells, including the epithelial cells that make up the mucosal lin-
ings of the body. These ancient compounds are important for the
innate defense of a eukaryotic host. They function within a matter
of hours, on a broad spectrum of bacteria, fungi, and encapsulated
viruses (reviewed in Weinberg et al., 1998; Zasloff, 2002; Hancock
et al., 2006). More recently, we and others have identified that
AMPs have the ability to work in conjunction with the adaptive
immune system by permitting the host to curb, delay, or avoid
microbial growth shortly after an infection.
hBDs AS SMALL CATIONIC AMPs OF EPITHELIAL CELL ORIGIN
Numerous organisms synthesize peptides which are processed into
smaller hydrophobic or amphipathic, bioactive peptides that act
as host defense mechanisms with several designations including;
magainins, cecropins, melittins, bacteriocidins, and defensins. In
animals, three structural defensin subfamilies, designated as alpha,
beta, and theta have been characterized, each possessing a distinc-
tive pattern of three canonical disulfide intramolecular bonds. In
mammals, defensins were among the first AMPs to be described.
Whileα-defensins are produced by polymorphonuclear leukocytes
and intestinal paneth cells, β-defensins are produced primarily by
epithelial cells. A computational search strategy identified 28 new
human β-defensin genes in five syntenic chromosomal regions.
At least 26 of the predicted genes were found to be transcribed.
This study focused on finding β-defensin second exons, the genetic
region encoding the mature peptide. It is anticipated that a similar
approach could be used to discover all first exon coding sequences
and the associated regulatory elements that confer cell speci-
ficity and responsiveness to inflammatory stimuli and pathogens
(Schutte et al., 2002). An additional five novel beta defensin genes
were identified using a bioinformatics approach by Rodriguez-
Jimenez et al. (2003) that clustered on chromosome 20p13 and that
the transcripts of which were found to be highest in the epididymis
of the male genital tract. hBD-2 and -3 are generally expressed at
low levels in normal physiological conditions and are induced in
response to microbial challenge, whereas hBD-1 is expressed at a
low level, with little regulation in response to infection or other
stimuli. β-defensins display antimicrobial as well as chemoattrac-
tant activities based upon the arrangement of disulfide bonds as
well as unidentified structural factors that confer full activity (Tay-
lor et al., 2008). β-defensins are mainly expressed in epithelial cells
(hBD-1-3 have been shown to be expressed and secreted in the
human oral cavity (Ghosh et al., 2007) and form pores in biologi-
cal membranes (Duclohier, 1994); their 3-D structures have been
previously published (Hoover et al., 2000, 2001).
Beta defensins, specific epithelial cell-derived AMPs (see
below),“cross-talk” with the adaptive immune system by interact-
ing with specific chemokine and toll-like receptors on myeloid and
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lymphoid cells, resulting in modulation of immunocompetent cell
responses of the host (Yang et al., 1999; Biragyn et al., 2001, 2002;
Quinones-Mateu et al., 2003; Feng et al., 2006; Funderburg et al.,
2007; Jin et al., 2010; Rohrl et al., 2010). It is theorized therefore,
that surveillance through epithelial cell-derived AMPs functions to
keep the natural flora of microorganisms in a steady state in differ-
ent niches such as the skin, the intestines, and the mouth (Yin, as
defined for the purpose of this review). However, there is new evi-
dence implicating some of these beneficial molecules as promoters
and contributors to neoplasia (Yang as defined for the purpose
of this review). Human beta defensin-3 (hBD-3), when overex-
pressed in epithelial cell-derived solid tumors, promotes selective
chemoattraction of myeloid cells to the lesion site and stimulates
them to secrete pro-inflammatory cytokines; i.e., contributing to
tumor growth (Kawsar et al., 2009; Jin et al., 2010). This review
will highlight recent findings, by our group, demonstrating that
human beta defensins are not just antimicrobial and immunoreg-
ulatory, but, in select pathological states, can contribute to the
exacerbation of neoplastic lesions.
HUMAN BETA DEFENSINS IN THE BODY
IN HEALTH AND DISEASE
The discoveries that β-defensins originate in mammalian mucosal
epithelium (Diamond et al., 1991; Schonwetter et al., 1995; Zhao
et al., 1996; Harder et al., 1997; McCray and Bentley, 1997; Boe
et al., 1999; O’Neil et al., 1999; Haynes et al., 2000; Garcia et al.,
2001; Harder and Schroder, 2002) has led to the hypothesis
that these AMPs function to protect the host against micro-
bial pathogenesis at critical confrontational sites. Our group has
extended this hypothesis to also encompass the oral epithelium
(Krisanaprakornkit et al., 1998, 2000; Weinberg et al., 1998; Dale
et al., 2001). The oral epithelia, and cells derived from it, con-
stitutively express human beta defensin-1 (hBD-1) and can be
induced to express hBD-2 and -3 (Krisanaprakornkit et al., 1998,
2000; Weinberg et al., 1998; Dunsche et al., 2002). From an
immunoregulatory perspective, β-defensins can engage a number
of cell surface receptors to promote chemotaxis. These include the
ability of hBD-2 to engage the CCR6 receptor on immature den-
dritic cells (DC) and T cells, and, in a chemokine manner, recruit
these cells to the site(s) of interest (Yang et al., 1999). Moreover,
we have shown that hBD-3 can down modulate the HIV co-
receptor CXCR4, leading to antagonism of cellular activity (Feng
et al., 2006). In addition, antigen presenting cells (APCs) undergo
maturation in the presence of hBD-3 via toll-like receptors 1,
2 (Funderburg et al., 2007). We and others have also observed
that hBD-3 demonstrates high affinity for interaction with CCR2
on myeloid cells (Jin et al., 2010; Rohrl et al., 2010) resulting in
chemoattraction in the absence of the natural ligand MCP-1/CCL2
(Jin et al., 2010). Finally, we have seen that hBD-3 can compete
with melanocyte stimulating hormone alpha (MSHα), the nat-
ural ligand of melanocortin 1 receptor (MC1r) in myeloid cells
(unpublished data). The latter observation suggests that hBD-3
may inhibit anti-inflammatory activity promoted by MSHα since
this ligand has been shown to induce IL-10 in cells expressing
MC1r (Luger et al., 2003).
In the human autoimmune disease psoriasis; epithelial tis-
sue contains high levels of human beta defensins (Harder et al.,
1997; Schroder and Harder, 1999; Zasloff, 2002; Sorensen et al.,
2003). Indeed, psoriasis skin was the organ used to identify human
epithelial production of beta defensin-2 and 3 (Harder et al., 1997,
2001). The recent discoveries that β-defensins originate in mam-
malian mucosal epithelium, including human (Diamond et al.,
1991; Schonwetter et al., 1995; Zhao et al., 1996; Harder et al.,
1997,2001; McCray and Bentley,1997; Boe et al.,1999; O’Neil et al.,
1999; Haynes et al., 2000; Garcia et al., 2001), has led to the hypoth-
esis that these AMPs function to protect the host against microbial
pathogenesis at these critical confrontational sites in healthy tissue
as well as immuno-compromised or challenged tissue. In addi-
tion to antibacterial and antifungal properties, β-defensins also
engage the CCR6 receptor on selected immune effector cells, such
as immature DC and T cells and evoke a chemokine response,
thereby recruiting these cells to the site of interest (Yang et al.,
1999). Furthermore, in addition to inducing dendritic cell matu-
ration (Biragyn et al., 2002) through toll-like receptor 4 (TLR4),
murine beta defensin-2 (mBD-2)-based vaccines are proposed to
elicit potent cell mediated responses and antitumor immunity
(Biragyn et al., 2002; see β-Defensins in Cancer). These recent
findings indicate that β-defensins are not only antimicrobial, but
may also be playing an important role in immunosurveillance by
locally helping break peripheral immune tolerance in organs dur-
ing acute infection/injury (as discussed further in β-Defensins in
Cancer).
Because hBD-2 and hBD-3 are found in extremely high levels
in psoriatic tissue, and since it appears that defensins can signal
through toll-like receptors that are expressed on cutaneous DC
and have been demonstrated on regulatory T cells (Caramalho
et al., 2003), it would be of great interest to determine if human
beta defensins participate in the activation of DC in psoriasis, i.e.,
through IL-6 upregulation by DC and releasing effector T cells
from local Treg cell suppression.
HBDs IN THE ORAL CAVITY
In gingival tissue, mRNA for both hBD-1 and -2 is localized in
suprabasal stratified epithelium and the peptides are detected in
upper epithelial layers consistent with the formation of the strat-
ified epithelial barrier (Dale et al., 2001; Figure 1). Our investiga-
tions into the distribution of hBD-3 expression in oral epithelium
suggests that while hBD-2 compartmentalizes to the more differ-
entiated stratum granulosum and spinosum, hBD-3 is expressed in
the less differentiated stratum basale (Kawsar et al.,2009; Figure 1);
further suggesting “cross-talk” capacity between this peptide and
resident immunocompetent cells. Most recently, hBD-3 has been
shown to be overwhelmingly produced in premalignant epithelial
cells in carcinoma in situ (CIS) and that this correlates with recruit-
ment and infiltration of monocytes/macrophages exclusively to
the lesion site (Jin et al., 2010).
EPITHELIAL DERIVED AMP-RELATED CHEMOTAXIS ACTIVITY AND
SPECIFICITY FOR RECEPTORS
Recent work in the area of epithelial cell-derived AMP activity
in recruiting immune cells has led to novel information show-
ing that these ancient molecules act as chemokines in recruiting
specific cells from the blood stream. The AMP referred to as LL-
37 (named after the first two N-terminal residues and the total
number of residues of the mature peptide), the only known cathe-
licidin like molecule expressed in humans (Zanetti, 2004), attracts
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FIGURE 1 | Distribution of hBD-2 and hBD-3 in normal oral epithelium.
Formalin fixed and parafilm embedded normal human oral tissue was
labeled with an anti-hBD-2 specific primary antibody (Santa Cruz, Santa
Cruz, CA, USA), and detected with AlexaFluor 488 (Invitrogen, CA, USA;
green) conjugated secondary antibody. hBD-3 was labeled with a rabbit
anti-hBD-3 (Novus Biologicals Inc., Littleton, CO, USA), specific primary
antibody and detected using an AlexaFluor 594 (purple) conjugated donkey
anti-rabbit (Invitrogen). Note green fluorescence detection of hBD-2
localized to the stratum spinosum and stratum granulosum, while pink/red
fluorescence detects hBD-3 exclusively to the stratum basale. hBD-1, not
shown, is localized to the same regions as hBD-2.
immune cells via interaction with the G protein coupled receptor
formyl peptide receptor-like 1 (FPRL1; De et al., 2000). We have
shown that hBD-3 has no effect on formyl-met-leu-phe recep-
tors, such as FPRL1 (Feng et al., 2006). Instead, hBD-3 interacts
with another G protein coupled receptor, CCR2, for chemotaxis
of myeloid type cells from the blood stream (Jin et al., 2010; Rohrl
et al., 2010). Moreover, while hBD-1 and hBD-2 were found to
recruit memory T cells and immature DC via the GPCR CCR6
(Yang et al., 1999), and while hBD-3 can mobilize cells expressing
CCR6 in vitro (Rohrl et al., 2008), it does not appear to be the case
in vivo, since hBD-3 exclusively recruits CCR2 expressing myeloid
cells at the exclusion of lymphoid cells into oral CIS lesions (Jin
et al., 2010).
Collectively, these data suggest that the “promiscuous” nature
of hBDs, through interaction with a number of surface associ-
ated cellular receptors can orchestrate selective cellular mobility,
change phenotypic traits of myeloid cells, and possibly promote a
micro environment conducive for inflammation (see Conclusion
below).
β-DEFENSINS AS IMMUNE REGULATORS
MATURATION OF iDC AND MONOCYTES BY hBD-3
The chemotactic responses of human monocytes and iDC to nano-
molar concentrations of hBD-3 provides a mechanism for cells to
move into inflamed tissues where hBD-3 concentrations may be
substantially higher. This raises the question of whether increased
exposure to hBD-3 might also influence the maturation and func-
tion of these cells as they migrate into inflammatory sites. A
key observation from murine studies provided the first indica-
tion that defensin molecules could cause activation of APCs via a
mechanism dependent on Toll-like receptors (TLRs; Biragyn et al.,
2002). TLRs are molecules that recognize conserved microbial
structures including, lipopeptides, which are components of bac-
terial cell walls and are recognized by TLR2, TLR1/2, and TLR1/6
molecules, lipopolysaccharide (LPS), a component of outer bacte-
rial cell membrane that is recognized by TLR4 and unmethylated
DNA sequences that are recognized by TLR9. Stimulation of TLRs
can lead to signaling mediated by MyD88 and downstream com-
ponents such as Mitogen Activated Protein Kinases (MAPKS) and
Nuclear Factor Kappa-Beta (NF-κB). The activation of APC by
a defensin molecule in a TLR-dependent manner suggested that
AMPs may not only serve to recruit cells of the adaptive immune
system into tissues but may also contribute to the function and
maturation of these cells.
In mice, the beta defensin-2 molecule was found to activate
APCs via a TLR4-dependent mechanism (Biragyn et al., 2002).
Although the relevance of the mouse studies were initially called
into question based on the potential for TLR4 contaminants in
recombinant defensin reagents (Kopp and Medzhitov, 2002) and
due to the lack of a human homolog to mouse defensin-2 (Ganz,
2002), it now seems clear that these initial observations do have rel-
evance to human biology. In particular, human beta defensin-3 has
been shown to activate human monocytes in a TLR1/2-dependent
manner (Funderburg et al., 2007). Notably, hBD-2, failed to acti-
vate cells in a similar manner suggesting that hBD-3 may be
uniquely poised to interact with these innate receptors.
Activation of human monocytes by hBD-3 results in several
substantial changes in these cells. Notably, hBD-3 induces co-
stimulatory molecule expression on human monocytes as well as
myeloid dendritic cells (mDC), including the heightened expres-
sion of CD80 and CD86 (Funderburg et al., 2007). These co-
stimulatory molecules are important ligands for CD28, which is
expressed on T cells and plays a critical role in T cell activation.
Monocytes activated by hBD-3 also express cytokines associated
with inflammation, including IL-8, IL-6, and IL-1β (Funderburg
et al., 2011). Importantly, unlike other TLR agonists such as the
TLR4 agonists LPS and the TLR1/2 agonist, PAM3CSK4, hBD-3
does not induce IL-10 in these cells (Funderburg et al., 2011). IL-10
is an important regulatory cytokine that suppresses APC func-
tion by down-modulating HLA-DR and co-stimulatory molecule
expression as well as inflammatory cytokine production by APCs
(Fiorentino et al., 1991a,b; Buelens et al., 1995; Chang et al., 1995;
Mottonen et al., 1998). Thus, the lack of IL-10 induction by hBD-3
compared to other TLR agonists suggests that hBD-3 may be more
prone to inducing a pro-inflammatory microenvironment.
Other investigators have also demonstrated production of
both hBD-1 and hBD-2 by DCs albeit at greatly reduced levels
of expression. However, in DCs both hBD-1 and hBD-2 were
inducible following bacterial exposure, while hBD-3 was only
weakly induced. These authors also report that both hBD-2 and
hBD-3 up-regulated the expression of IL-8 and GRO in DCs while
differential regulation of IL-6 by hBD-2 and MCP-1 by hBD-3 was
observed (Yin et al., 2010).
Despite the induction of co-stimulatory molecules and
cytokines, not all of hBD-3’s activities seem to be pro-
inflammatory. For example, hBD-3 is also capable of modulat-
ing innate immunity by neutralization of LPS (Semple et al.,
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2010). This property is not unique to hBD-3 as other cationic
AMPs such as the cathelicidin LL-37, have similar LPS neutraliz-
ing activity (Nagaoka et al., 2001; Scott et al., 2011; Suphasiriroj
et al., 2012). The neutralization of endotoxin by AMPs is
likely to stem from direct binding interactions and the effec-
tiveness of the interaction can be influenced by the source
of LPS (Lee et al., 2010). Ultimately, the net effect of hBD-3
on inflammation and bacterial challenge is likely to be com-
plex and will require in vivo and in situ approaches to fully
discern.
HBD-3 AS A MUCOSAL ADJUVANT
There are relatively sparse vaccine adjuvant approaches that are
currently available in clinical practice and few that target T cell
immunity and mucosal applications. One recent advance in this
area is the development of a TLR4 agonist, monophosphoryl lipid
A (MPLA), as an adjuvant (Casella and Mitchell, 2008). This mol-
ecule is a derivative of LPS that stimulates cells via TLR4. MPLA
provides adequate stimulation for adaptive immune responses
but lacks some of the toxicities associated with the parent mol-
ecule. The mechanism for MPLA’s success is not fully discerned,
although it may be related to a relative skewing of TLR4 signaling in
the TRIF-dependent pathway rather than the MyD88-dependent
pathway (Mata-Haro et al., 2007). The diminished ability of MPLA
to induce certain cytokines in comparison to LPS may account
in part, for its better safety profile (Salkowski et al., 1997). The
progress made with MPLA has created further enthusiasm for
developing TLR agonists as vaccine adjuvants.
Although the full range of hBD-3 activity in vivo is likely to be
complex and related to the specific tissues and inflammatory con-
ditions in which it is associated, observations made thus far in vivo
and in vitro, have raised the possibility of considering defensin
molecules and other AMPs for development as vaccine adju-
vants. Immunization studies in mice suggest that hBD-3 and other
AMPs can enhance antibody responses to protein antigens in vivo
(Tani et al., 2000; Brogden et al., 2003; Kohlgraf et al., 2010a,b).
hBD-3, for example, boosted IgG responses in mice immunized
with intranasal administration of recombinant hemagglutinin B
or fimbriae A proteins that are products of Porphyromonas gin-
givalis (Kohlgraf et al., 2010a). hBD-2 mediated similar activity
when co-administered intranasally with ovalbumin (OVA) protein
(Brogden et al., 2003). Interestingly, murine defensin-2, the TLR4
agonist, was recently used in a tumor vaccination study where
the gene for mBD-2 was inserted into B16 melanoma cells and
these cells were used for immunization (Mei et al., 2012). Immu-
nization with mBD-2-expressing cells provided protection in mice
subsequently challenged with tumor cells and this was dependent
on both CD4+ and CD8+ T cells. NK cell activation was also
implicated as a mechanism of protection, suggesting that innate
immune mechanisms could also be targeted by this approach.
The in vitro studies with human cells demonstrate the capacity
of hBD-3 to chemoattract APC in a CCR2-dependent manner
(Jin et al., 2010; Rohrl et al., 2010) and to further activate these
cells in a TLR1/2-dependent manner (Funderburg et al., 2007).
Importantly, the identification of these receptor interactions pro-
vides a defined mechanism by which hBD-3 can link innate and
adaptive defenses.
The involvement of TLR1/2 stimulation in hBD-3 activity may
provide some indication of this molecule’s potential adjuvant
activity. Although less studied than a number of other TLR path-
ways for vaccine adjuvant applications, the TLR1/2 signaling path-
way was recently shown to be important for immune responses
to outer-surface lipoprotein (OspA) in a vaccination strategy for
Borrelia burgdorferi as mice lacking TLR1 and TLR2 display poor
responses to immunization (Alexopoulou et al., 2002). Similarly,
TLR2 has been implicated as a critical factor in CD4+ T cell
responses to the outer membrane protein (OmpA) of Shigella
flexneri (Pore et al., 2012). Moreover, vaccine adjuvant activity
of LT-IIa-B (Rodriguez-Jimenez et al., 2003), derived from entero-
toxin, and Chlamydia major OmpA have both been linked to TLR2
activation (Cheng et al., 2011; Lee et al., 2011). Not all studies have
shown enhanced adaptive immune responses with TLR2 agonists,
however, as these molecules sometimes lead to high induction of
IL-10 and potential downregulation of immune responses in cer-
tain circumstances (Netea et al., 2004). Thus, the TLR1/2 agonist
activity of hBD-3, coupled with its apparent inability to induce
IL-10 production from APC (Funderburg et al., 2011), may pro-
vide an advantage for induction of adaptive immune responses
compared to other more conventional TLR2 stimulants.
β-DEFENSINS IN CANCER
EXPRESSION OF HUMAN β-DEFENSINS IN CANCERS
The discovery of human β-defensins has led to the recognition
of the defense mechanism of mucosal surfaces to protect the
host from potentially pathogenic organisms. In addition to their
antimicrobial activity, the expression of β-defensins in various tis-
sues and cell types has been linked with chemotaxis and innate
immune signaling, adaptive immunity, wound healing, and car-
cinogenesis. Abiko et al. (1999) were the first to describe the
detection of human β-defensin-1 and -2 mRNAs in oral can-
cer cell lines and in tumor samples in an attempt to correlate
bacterial infection with the process of oral carcinogenesis. Fur-
ther reports have shown that hBD-2 peptide was observed in
cancer cells in the cornified region of well differentiated oral squa-
mous cell carcinomas (OSCC) and in the hyper-keratinized oral
epithelium of oral cancer biopsies (Mizukawa et al., 2000; Abiko
et al., 2001; Sawaki et al., 2002). In oral mucoepidermoid car-
cinoma tissues, neutrophils, and cancer cells that constitute the
ducts were positively immunostained with anti-α-defensin anti-
body (human neutrophil peptides, HNPs), whereas epidermoid
cells and intermediate cells were intensely stained with the anti-
hBD-2 antibody (Mizukawa et al., 2001). In addition to oral cancer,
chromophobe renal cell carcinomas and oncocytomas, two com-
mon histopathologic subtypes of renal epithelial neoplasms, were
immunohistochemically positive for hBD-1 (Young et al., 2003).
Recent studies have investigated expression of hBDs in normal and
malignant tissues to elicit the role of β-defensins in carcinogenesis.
Kawsar et al. (2009) have found that hBDs are spatiotemporally
expressed in normal, non-cancerous oral epithelium and precan-
cerous, and malignant lesions of the oral cavity. In normal oral
epithelia, co-expression of hBD-1 and -2 is primarily associated
with differentiated epithelial cells in the superficial layers, how-
ever, hBD-3 is produced predominantly by mitotically active cells
in the basal layer, similar to what was reported by Lu et al. (2005)
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in gingival epithelium (Kawsar et al., 2009). Interestingly, tumor
cells in oral CIS lesions exclusively produce hBD-3, correlated with
expression of proliferating cell nuclear antigen (PCNA) in these
cells (Kawsar et al., 2009). In addition, precancerous cells in mod-
erate dysplastic lesions and mitotically active malignant cells at
the edges of terminally differentiated OSCC only produce hBD-3,
suggesting that hBD-3 expression may recapitulate the molecular
events of malignant transformation of oral epithelial cells. Kesting
et al. (2009) investigated hBD-3 expression in paired cancerous
and non-cancerous specimens of 45 patients to establish the asso-
ciation of hBD-3 expression and stages of OSCC. The expression of
hBD-3 is significantly up-regulated in OSCC samples compared to
corresponding healthy oral mucosa and normal mucosal samples.
In addition, immunofluorescence stain of hBD-3 is much more
intense in OSCC tissues than in healthy mucosa (Kesting et al.,
2009). However, no significant dependence of hBD-3 mRNA lev-
els correlating with tumor size, histological differentiation, cervical
lymph node status, or stage of the cancers was found (Kesting et al.,
2009).
REGULATION OF β-DEFENSIN EXPRESSION
Expression of human β-defensins (hBDs) can be induced by
transcription factors that are activated following initiation of var-
ious signaling pathways. Analyses using cultured oral epithelial
cells have shown that hBD-1 is constitutively expressed (Jure-
vic et al., 2003), whereas hBD-2 and hBD-3 are inducible (Dale
et al., 2001; Pazgier et al., 2006; Yang et al., 2007). However,
in vivo studies using RNA in situ hybridization and immuno-
histochemistry have linked the expression profile of hBDs with
the status of cellular differentiation and state of disease, indicat-
ing that expression of hBDs is context-dependent (Dale et al.,
2001; Kawsar et al., 2009, 2010; Kesting et al., 2009; Jin et al.,
2010). Indeed, the cellular proliferation marker, PCNA, is co-
localized with hBD-3 expressing cells in the epithelial basal cell
layer and in tumors of the oral cavity (Kawsar et al., 2009).
In addition, nuclear translocation of β-catenin, a transcrip-
tion modulator participating in tumorigenesis, has been iden-
tified in cells residing only in the CIS lesion, but not in cells
of the adjacent normal region (Kawsar et al., 2009). Expres-
sion of hBD-3 is induced by epidermal growth factor (EGF)
via MAPK kinase MEK1/2, PKC, PI3K, and p38 MAPK signal-
ing cascades, but not the signal transducers and activator of
transcription (STATs) proteins in oral epithelial cells (Kawsar
et al., 2009). In addition, transactivation of EGF receptor dur-
ing human skin wound healing stimulates hBD-3 expression in
skin keratinocytes (Sorensen et al., 2006). While signaling path-
ways that regulate expression of hBD-1 still remain unknown,
hBD-2 is induced by pro-inflammatory mediators or bacterial
products via activation of NF-κB transcription factors and STATs
(Boughan et al., 2006; Chung and Dale, 2008). Kawsar et al.
(2010) have shown the expression of hBD-2 in microvascula-
ture in the “keratin pearl” region of terminally differentiated
OSCC. In addition, endothelial spindle cells in Kaposi’s sar-
coma produce hBD-2 (Kawsar et al., 2010). Interestingly, TGFβ-1
induces hBD-2 expression in human umbilical vein endothelial
cells, but not in oral epithelial cells, suggesting that the induc-
tion of hBD-2 expression by TGFβ is endothelial cell specific
(Kawsar et al., 2010). These data indicate that expression of β-
defensins can be regulated by multiple signaling pathways and is
cell type-dependent.
β-DEFENSINS AND TUMORIGENESIS
Studies of β-defensin involvement in tumor development and pro-
gression have indicated that β-defensins may play important roles
in tumorigenesis. Conejo-Garcia et al. (2004) demonstrated that
β-defensins can recruit CD11c+ DC precursors through CCR6
into tumorigenic areas where vascular endothelial growth factor-A
(VEGF-A) transforms them into endothelial-like cells that engage
in vasculogenesis and function as promoters of tumor progres-
sion in an ovarian mouse model. In human epithelial ovarian
neoplasms, hBD-2 peptide has been detected in most ovarian can-
cers with the strongest expression in tumor islets, while hBD-3
expression has been identified in all cancer specimens analyzed
(45/45; Conejo-Garcia et al., 2004). Interestingly, populations of
CD11c+ leukocytes isolated from freshly dispersed human ovarian
cancer express endothelial as well as DC markers, indicating that
tumor cell-derived β-defensin molecules may contribute to the
recruitment and, in the presence of VEGF-A, endothelial cell-like
differentiation of CD11c+ DCs in human ovarian cancer (Conejo-
Garcia et al., 2004). Nevertheless, numerous tumor types have been
shown to have altered receptor expression that enables the tumors
to respond to many growth factors, hormones, and cytokines in an
autocrine fashion that have the capacity to promote tumor growth
to the detriment of the host. Therefore, we should not be sur-
prised that tumors may also respond to self-produced defensins in
a similar manner.
Work by Pantelis et al. demonstrated a decrease in hBD-1 gene
expression in pleomorphic adenomas compared to healthy and
chronic inflamed salivary gland tissue. They suggest that reduced
hBD-1 gene expression and altered hBD-1 protein localization
from the cytoplasm to the nucleus might play a potential role in
tumor development (Pantelis et al., 2009). Indeed, Wenghoefer
et al. (2008) have also previously shown that hBD-1 seems to be
shifted from the cytoplasm to the nucleus of malignant salivary
gland tumors and these authors hypothesize that the nuclear shift
of hBD-1 might be associated with malignancy.
Kawsar et al. (2009) have shown that oral tumor cell-derived
hBD-3 is associated with accumulation of CD68+ macrophages,
but not CD3+ lymphocytes, in the tumor site, suggesting hBD-
3 involvement in recruitment of tumor-associated macrophages
(TAMs). To further elucidate the role of tumor cell-produced
hBD-3 in oral tumorigenesis, Jin et al. (2010) have shown that
tumor cells in oral CIS lesions produce hBD-3,but not macrophage
chemotactic protein-1 (MCP-1/CCL2), a known chemokine for
macrophage migration, and that hBD-3 chemoattracts mono-
cytes/macrophages. Pretreatment of human monocytes with
MCP-1, which binds to CCR2, or RS102895, the CCR2-specific
inhibitor, inhibits hBD-3-induced migration of monocytes, indi-
cating that hBD-3 plays an important role in recruiting TAMs via
CCR2 (Jin et al., 2010; Rohrl et al., 2010). In addition, hBD-3
and MCP-1 fail to chemoattract monocytes from CCR2 knock-
out mice (Rohrl et al., 2010). TAMs often make up a significant
part of infiltrating immune cells in the tumor microenviron-
ment thereby establishing the inflammatory micromilieu, which
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often belies a poor prognosis for the patient (de Visser et al.,
2006; Allavena et al., 2008; Biswas et al., 2008). TAMs have poor
antigen presenting capacity, exhibit an immunosuppressive phe-
notype, and release pro-tumor cytokines such as IL-6 and TNFα,
upon activation (Pollard, 2004; Allavena et al., 2008). Stimula-
tion of human macrophages with hBD-3 induces expression of
tumor-promoting cytokines and chemokines, including IL-1α,
IL-6, IL-8, CCL18, CCL24, and TNF-α. These data indicate that
hBD-3 is important in establishing a tumor-associated inflam-
matory environment by recruiting monocytes from the periph-
eral blood and stimulating TAMs to produce chemokines and
cytokines that support growth and progression of tumors (Jin
et al., 2010).
CONCLUSION
This review brings into question the notion that AMPs are only
released by specific host cells to protect the host from microbial
challenges, be they bacterial, fungal, or viral. AMPs have the capac-
ity to serve as chemokines when secreted in nano-molar (nM)
concentrations and as regulators of cell maturity and phenotypic
change when present in low micro-molar (µM) concentrations.
This is best exemplified by hBD-3 where when present in nM
concentrations promotes the recruitment of immature myeloid
cells from the blood, via the surface receptor CCR2, to hBD-3
rich sites in the body, such as the stratum basale of the mucosa.
Once in the tissue, recruited cells undergo maturation through
heterodimerization of TLR 1 and 2 in the presence of low µM
FIGURE 2 |Yin andYang of human beta defensins. Defensins and
their homologs are elicited and produced by epithelial cells in
response to various stimuli including wounding, bacterial challenge
(such as the oral bacteria Fusobacterium nucleatum; Gupta et al.,
2010), or tumor development (Carcinoma in situ, as shown).
Defensins modulate the immune-regulatory response to bolster the
host response toward challenge. Alternatively defensins may
chemoattract immune cells such as tumor-associated macrophages
that contribute to tumor-related inflammation and protection of
tumors from immune surveillance.
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levels of hBD-3. Interestingly, in situations where there is overex-
pression of hBD-3 and little-to-no expression of MCP-1 (CCL2),
such as in oral CIS, there is chemoattraction and activation of
tumor-associated macrophages that contribute to tumor-related
inflammation and protection of tumors from immune surveil-
lance. This is the Yin Yang story of hBD-3 (Figure 2). On the one
hand defensins and their homologs may one day be exploited to
modulate immune-regulatory strategies as a translational option
to bolster the native host response toward, for example, micro-
bial challenge; i.e., novel adjuvants; on the other hand, defensins
may be a biomarker for epithelial derived solid tumors and
possibly a target in anti-neoplastic intervention. Current and
future studies will determine if these two divergent possibilities
indeed capture the full range of diversity for these antimicrobial
molecules.
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